Updates are available Correction dated 2022-12-17
Click to view Correction: https://doi.org/10.1007/s00428-022-03475-5
-
Authors
Pisacane, Alberto
Cascardi, Eliano http://orcid.org/0000-0003-1287-4285
Berrino, Enrico
Polidori, Alessio
Sarotto, Ivana
Casorzo, Laura
Panero, Mara
Boccaccio, Carla
Verginelli, Federica
Benvenuti, Silvia
Dellino, Miriam
Comoglio, Paolo
Montemurro, Filippo
Geuna, Elena
Marchiò, Caterina
Sapino, Anna
- License Information
-
More Information
Article History
Received: 22 July 2022
Revised: 10 October 2022
Accepted: 15 October 2022
First Online: 8 November 2022
Change Date: 17 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00428-022-03475-5
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Candiolo Cancer Institute, FPO-IRCCS (Study Protocol N. 010-IRCC-10IIS-15 and following updates; last update: v2.0–16.10.2018).
: Written informed consent was obtained by all patients.
: PMC is a shareholder of Metis. CM reports personal consultancy fees from Roche, Bayer, Daiichi Sankyo, and AstraZeneca, outside the scope of the present work. FM reports personal fees for consultancy or speaker’s engagements from Roche, Novartis, Pfizer, AstraZeneca, MSD, Eli Lilly, Daiichi Sankyo, and SeaGen, outside the scope of the present work.
